Granules pioneered the concept of commercializing PFIs or Pre formulation Intermediates, with objective to reduce cost economics of productS and to enable ease of operations for the manufacturer. PFIs enable “drum to hopper to compression/ encapsulation,” which offer cost and quality advantages on the supply chain, testing, technical and capital resources fronts at finished dosage manufacturers’ site. Not all molecules have properties that are amenable to be converted into PFIs. Hence, at the PFI R&D unit, we work on identifying and scaling up PFIs for molecules that have a sustainable market presence and focus on bringing in continuous cost efficiencies.